Journal of Clinical Oncology, Vol 16, 3493-3501, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients

CL Shapiro, PH Hardenbergh, R Gelman, D Blanks, P Hauptman, A Recht, DF Hayes, J Harris and IC Henderson
Breast Evaluation Center and Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA. shapiro-1@medctr.osu.edu

PURPOSE: To assess the cardiac effects of two different cumulative doses of adjuvant doxorubicin and radiation therapy (RT) in breast cancer patients. PATIENTS AND METHODS: Two hundred ninety-nine breast cancer patients were prospectively randomized to receive either five cycles (CA5) or 10 cycles (CA10) of adjuvant treatment with cyclophosphamide (500 mg/ m2) and doxorubicin (45 mg/m2) administered by intravenous bolus every 21 days. One hundred twenty-two of these patients also received RT. Estimates of the cardiac RT dose-volume were retrospectively categorized as low, moderate, or high. The risk of major cardiac events (congestive heart failure, acute myocardial infarction) was assessable in 276 patients (92%), with a median follow- up time of 6.0 years (range, 0.5 to 19.4). RESULTS: The estimated risk (95% confidence interval) of cardiac events per 100 patient-years was significantly higher for CA10 than for CA5 [1.7 (1.0 to 2.8) v 0.5 (0.1 to 1.2); P=.02]. The risk of cardiac events in CA5 patients, irrespective of the cardiac RT dose-volume, did not differ significantly from rates of cardiac events predicted for the general female population by the Framingham Heart Study. In CA10 patients, the incidence of cardiac events was significantly increased (relative risk ratio, 3.6; P < .00003) compared with the Framingham population, particularly in groups that also received moderate and high dose-volume cardiac RT. CONCLUSION: Conventional-dose adjuvant doxorubicin as delivered in the CA5 regimen by itself, or in combination with locoregional RT, was not associated with a significant increase in the risk of cardiac events. Higher doses of adjuvant doxorubicin (CA10) were associated with a threefold to fourfold increased risk of cardiac events. This appears to be especially true in patients treated with higher dose-volumes of cardiac RT. Larger studies with longer follow-up periods are needed to confirm these results.

This article has been cited by other articles:

				S. Bhatia and L. L. Robison Cancer Survivorship Research: Opportunities and Future Needs for Expanding the Research Base Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1551 - 1557. [Full Text] [PDF]

				J. R. Carver, C. L. Shapiro, A. Ng, L. Jacobs, C. Schwartz, K. S. Virgo, K. L. Hagerty, M. R. Somerfield, D. J. Vaughn, and for the ASCO Cancer Survivorship Expert Panel American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects J. Clin. Oncol., September 1, 2007; 25(25): 3991 - 4008. [Abstract] [Full Text] [PDF]

				C. R. Correa, H. I. Litt, W.-T. Hwang, V. A. Ferrari, L. J. Solin, and E. E. Harris Coronary Artery Findings After Left-Sided Compared With Right-Sided Radiation Treatment for Early-Stage Breast Cancer J. Clin. Oncol., July 20, 2007; 25(21): 3031 - 3037. [Abstract] [Full Text] [PDF]

				S. C. Formenti, D. Gidea-Addeo, J. D. Goldberg, D. F. Roses, A. Guth, B. S. Rosenstein, and K. J. DeWyngaert Phase I-II Trial of Prone Accelerated Intensity Modulated Radiation Therapy to the Breast to Optimally Spare Normal Tissue J. Clin. Oncol., June 1, 2007; 25(16): 2236 - 2242. [Abstract] [Full Text] [PDF]

				M. J. Hooning, A. Botma, B. M. P. Aleman, M. H. A. Baaijens, H. Bartelink, J. G. M. Klijn, C. W. Taylor, and F. E. van Leeuwen Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast Cancer J Natl Cancer Inst, March 7, 2007; 99(5): 365 - 375. [Abstract] [Full Text] [PDF]

				K. C. Oeffinger and M. S. McCabe Models for Delivering Survivorship Care J. Clin. Oncol., November 10, 2006; 24(32): 5117 - 5124. [Abstract] [Full Text] [PDF]

				A. Recht Which Breast Cancer Patients Should Really Worry About Radiation-Induced Heart Disease--And How Much? J. Clin. Oncol., September 1, 2006; 24(25): 4059 - 4061. [Full Text] [PDF]

				P. Fumoleau, H. Roche, P. Kerbrat, J. Bonneterre, P. Romestaing, P. Fargeot, M. Namer, A. Monnier, P. Montcuquet, M.-J. Goudier, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results Ann. Onc., January 1, 2006; 17(1): 85 - 92. [Abstract] [Full Text] [PDF]

				E. Mrozek, C. A. Rhoades, J. Allen, E. M. Hade, and C. L. Shapiro Phase I trial of liposomal encapsulated doxorubicin (MyocetTM; D-99) and weekly docetaxel in advanced breast cancer patients Ann. Onc., July 1, 2005; 16(7): 1087 - 1093. [Abstract] [Full Text] [PDF]

				L. J. Pierce The Use of Radiotherapy After Mastectomy: A Review of the Literature J. Clin. Oncol., March 10, 2005; 23(8): 1706 - 1717. [Full Text] [PDF]

				S. Chan, N. Davidson, E. Juozaityte, F. Erdkamp, A. Pluzanska, N. Azarnia, and L. W. Lee Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer Ann. Onc., October 1, 2004; 15(10): 1527 - 1534. [Abstract] [Full Text] [PDF]

				J. Bonneterre, H. Roche, P. Kerbrat, P. Fumoleau, M.-J. Goudier, P. Fargeot, P. Montcuquet, P. Clavere, J.-C. Barats, A. Monnier, et al. Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group J. Clin. Oncol., August 1, 2004; 22(15): 3070 - 3079. [Abstract] [Full Text] [PDF]

				P. T. Truong, I. A. Olivotto, T. J. Whelan, and M. Levine Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy Can. Med. Assoc. J., April 13, 2004; 170(8): 1263 - 1273. [Abstract] [Full Text] [PDF]

				B. F. Byrd III and L. A. Mendes Cardiac complications of mediastinal radiotherapy: The other side of the coin J. Am. Coll. Cardiol., August 20, 2003; 42(4): 750 - 751. [Full Text] [PDF]

				F. Stevanato, P. Pancotto, P. Reimers, L. Salvano, and G. Cella Revascularization for Acute Coronary Occlusion in a Young Woman Following Radiation Clinical and Applied Thrombosis/Hemostasis, July 1, 2003; 9(3): 265 - 266. [PDF]

				C. E. Holmes and H. B. Muss Diagnosis and Treatment of Breast Cancer in the Elderly CA Cancer J Clin, July 1, 2003; 53(4): 227 - 244. [Abstract] [Full Text]

				I. C. Henderson, D. A. Berry, G. D. Demetri, C. T. Cirrincione, L. J. Goldstein, S. Martino, J. N. Ingle, M. R. Cooper, D. F. Hayes, K. H. Tkaczuk, et al. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer J. Clin. Oncol., March 15, 2003; 21(6): 976 - 983. [Abstract] [Full Text] [PDF]

				P. Fumoleau, P. Kerbrat, P. Romestaing, P. Fargeot, A. Bremond, M. Namer, S. Schraub, M.-J. Goudier, J. Mihura, A. Monnier, et al. Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial J. Clin. Oncol., January 15, 2003; 21(2): 298 - 305. [Abstract] [Full Text] [PDF]

				I. Goethals, O. De Winter, P. De Bondt, J. De Sutter, R. Dierckx, and C. Van De Wiele The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage Ann. Onc., September 1, 2002; 13(9): 1331 - 1339. [Abstract] [Full Text] [PDF]

				D. L. Keefe The Cardiotoxic Potential of the 5-HT3 Receptor Antagonist Antiemetics: Is There Cause for Concern? Oncologist, February 1, 2002; 7(1): 65 - 72. [Abstract] [Full Text] [PDF]

				L. J. Pierce Treatment Guidelines and Techniques in Delivery of Postmastectomy Radiotherapy in Management of Operable Breast Cancer J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 117 - 124. [Abstract] [Full Text] [PDF]

				A. H. Partridge, H. J. Burstein, and E. P. Winer Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 135 - 142. [Abstract] [Full Text] [PDF]

				C. L. Shapiro and A. Recht Side Effects of Adjuvant Treatment of Breast Cancer N. Engl. J. Med., June 28, 2001; 344(26): 1997 - 2008. [Full Text] [PDF]

				M.T. Meinardi, D.J. van Veldhuisen, J.A. Gietema, W.V. Dolsma, F. Boomsma, M.P. van den Berg, C. Volkers, J. Haaksma, E.G.E. de Vries, D.Th. Sleijfer, et al. Prospective Evaluation of Early Cardiac Damage Induced by Epirubicin-Containing Adjuvant Chemotherapy and Locoregional Radiotherapy in Breast Cancer Patients J. Clin. Oncol., May 15, 2001; 19(10): 2746 - 2753. [Abstract] [Full Text] [PDF]

				D. M. Green, Y. A. Grigoriev, B. Nan, J. R. Takashima, P. A. Norkool, G. J. D'Angio, and N. E. Breslow Congestive Heart Failure After Treatment for Wilms' Tumor: A Report From the National Wilms' Tumor Study Group J. Clin. Oncol., April 1, 2001; 19(7): 1926 - 1934. [Abstract] [Full Text] [PDF]

				A. Recht, S. B. Edge, L. J. Solin, D. S. Robinson, A. Estabrook, R. E. Fine, G. F. Fleming, S. Formenti, C. Hudis, J. J. Kirshner, et al. Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 1, 2001; 19(5): 1539 - 1569. [Abstract] [Full Text] [PDF]

				Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of French Adjuvant Study Group 05 Randomized Trial J. Clin. Oncol., February 1, 2001; 19(3): 602 - 611. [Abstract] [Full Text] [PDF]

				M. Zambetti, A. Moliterni, C. Materazzo, M. Stefanelli, S. Cipriani, P. Valagussa, G. Bonadonna, and L. Gianni Long-Term Cardiac Sequelae in Operable Breast Cancer Patients Given Adjuvant Chemotherapy With or Without Doxorubicin and Breast Irradiation J. Clin. Oncol., January 1, 2001; 19(1): 37 - 43. [Abstract] [Full Text] [PDF]

				H. J. Burstein and E. P. Winer Primary Care for Survivors of Breast Cancer N. Engl. J. Med., October 12, 2000; 343(15): 1086 - 1094. [Full Text] [PDF]

				T. J. Whelan, J. Julian, J. Wright, A. R. Jadad, and M. L. Levine Does Locoregional Radiation Therapy Improve Survival in Breast Cancer? A Meta-Analysis J. Clin. Oncol., March 13, 2000; 18(6): 1220 - 1229. [Abstract] [Full Text] [PDF]

				A. Gennari, B. Salvadori, S. Donati, C. Bengala, C. Orlandini, R. Danesi, M. Del Tacca, P. Bruzzi, and P. F. Conte Cardiotoxicity of Epirubicin/Paclitaxel-Containing Regimens: Role of Cardiac Risk Factors J. Clin. Oncol., November 1, 1999; 17(11): 3596 - 3602. [Abstract] [Full Text] [PDF]

				J. Clin. Oncol., July 1, 1999; 17(7): 2293c - 2293. [PDF]